Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

The Case for Prostate Brachytherapy in the Affordable Care Act Era

Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor.

Volume 102, Issue 4, Pages (October 1992)

The Use of Hormone Therapy Alone Versus Hormone Therapy and Radiation Therapy for Breast Cancer in Elderly Women: A Population-Based Study Alan M. Nichol,

18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy

Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With.

Close or Positive Margins After Mastectomy for DCIS: Pattern of Relapse and Potential Indications for Radiotherapy Afshin Rashtian, M.D., Shawn Iganej,

A New Model for Imaging and Radiation Therapy Quality Assurance in the National Clinical Trials Network of the National Cancer Institute Thomas J. FitzGerald,

Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast.

Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma

Trine Grantzau, Mette Skovhus Thomsen, Michael Væth, Jens Overgaard

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Feasibility and Potential Utility of Multicomponent Exhaled Breath Analysis for Predicting Development of Radiation Pneumonitis After Stereotactic Ablative.

Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation Makoto Hoshino, MD, Yutaka Nakamura, MD,

Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9.

Regulation of vascular smooth muscle cell expression and function of matrix metalloproteinases is mediated by estrogen and progesterone exposure Oscar.

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Weiguo Chen, MD, PhD, Yasuhiro Tabata, MD, PhD, Aaron M

Simultaneous analysis of 1176 gene products in normal human aorta and abdominal aortic aneurysms using a membrane-based complementary DNA expression array

Response of plasma matrix metalloproteinases and tissue inhibitor of metalloproteinases to stent-graft surgery for descending thoracic aortic aneurysms

Cardiac surgery increases the activity of matrix metalloproteinases and nitric oxide synthase in human hearts Irvin Mayers, MD, Thomas Hurst, MVSc, Lakshmi.

Cannabinoid WIN-55,212-2 mesylate inhibits interleukin-1β induced matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase expression.

Prospective Assessment of Patient-Rated Symptoms Following Whole Brain Radiotherapy for Brain Metastases Edward Chow, MBBS, Lori Davis, PhD, Lori Holden,

Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content Hazem Abdul-Hussien, MD, Roeland Hanemaaijer,

Chandra Goparaju, PhD, Jessica S

Electronic Updates for JTO Readers

Bullous pemphigoid outcome is associated with CXCL10-induced matrix metalloproteinase 9 secretion from monocytes and neutrophils but not lymphocytes

Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib Sai-Hong Ignatius Ou, MD, PhD,

Richard R. Keen, MD, Kevin D

Elevated messenger RNA expression and plasma protein levels of osteopontin and matrix metalloproteinase types 2 and 9 in patients with ascending aortic.

Matrix metalloproteinases modulated by protein kinase Cε mediate resistin-induced migration of human coronary artery smooth muscle cells Qinxue Ding,

Turning Gray: The Natural History of Lung Cancer Over Time

Frank Detterbeck, MD Journal of Thoracic Oncology

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Timeliness Across the Continuum of Care in Veterans with Lung Cancer

Matrix metalloproteinase and tissue inhibitor expression in atherosclerotic and nonatherosclerotic thoracic aortic aneurysms Joseph D. Schmoker, MD,

Temporal disparity in the induction of matrix metalloproteinases and tissue inhibitors of metalloproteinases after thoracic aortic aneurysm formation

“The Best-Laid Plans … Often go Awry …”

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9.

Heavy Smoking Before Coronary Surgical Procedures Affects the Native Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 Gene Expression in Saphenous.

Mitotic Inhibitors Journal of Thoracic Oncology

Morphologic characteristics of varicose veins: possible role of metalloproteinases Kenneth J Woodside, MD, Mingdao Hu, MD, Ann Burke, MS, Maki Murakami,

In vitro differences between smooth muscle cells derived from varicose veins and normal veins Ying Xiao, PhD, Zhibin Huang, MD, Henghui Yin, PhD, Ying.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Metalloproteinase expression in venous aneurysms

Volume 5, Issue 2, Pages (September 1998)

Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease Esther Martinez-Aguilar, MD,

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

High Frequency of Radiation Pneumonitis in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Concurrent Radiotherapy and Gemcitabine.

Genetic Changes in Squamous Cell Lung Cancer: A Review

European Lung Cancer Conference (ELCC) 2016 Organisation

Andreas Rimner, MD, Kenneth E. Rosenzweig, MD

Intrathoracic Desmoid Tumor: Brief Report and Review of Literature

Wanfen Xiong, MD, PhD, Rebecca Knispel, BS, Jason Mactaggart, MD, B

Effects of propofol on the expression of matric metalloproteinases in rat cardiac fibroblasts after hypoxia and reoxygenation J.H. Jun, J.E. Cho, Y.H.

David Garfield, MD Journal of Thoracic Oncology

Altered circulating levels of matrix metalloproteinases 2 and 9 and their inhibitors and effect of progesterone supplementation in women with endometriosis.

Chronic Pseudomonas aeruginosa Pneumonia in a Normal Adult

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Matrix metalloproteinase (MMP-1) and tissue inhibitor of MMP in peritoneal fluids and sera and correlation with peritoneal adhesions Nasser Chegini,

John S. Ikonomidis, MD, PhD, Charlotte R. Ivey, BS, Jason B

Presentation transcript:

Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy Herbert Susskind, P.E., M.Ch.E., Michelle H Hymowitz, B.S., Yat Hong Lau, M.D., Harold L Atkins, M.D., Adam N Hurewitz, M.D., Edward S Valentine, M.D., Allen G Meek, M.D., Stanley Zucker, M.D. International Journal of Radiation Oncology • Biology • Physics Volume 56, Issue 4, Pages 1161-1169 (July 2003) DOI: 10.1016/S0360-3016(03)00161-5

Fig. 1 Temporal variation of plasma MMP-9 assays in all subjects. Heavy dotted horizontal lines denote normal range (29 ± 11 ng/mL). International Journal of Radiation Oncology • Biology • Physics 2003 56, 1161-1169DOI: (10.1016/S0360-3016(03)00161-5)

Fig. 2 Temporal variation of plasma TIMP-1 assays in all subjects. Heavy dotted horizontal lines denote normal range (436 ± 86 ng/mL). International Journal of Radiation Oncology • Biology • Physics 2003 56, 1161-1169DOI: (10.1016/S0360-3016(03)00161-5)

Fig. 3 Temporal variation of plasma MMP-9 and TIMP-1 in Subject 5. International Journal of Radiation Oncology • Biology • Physics 2003 56, 1161-1169DOI: (10.1016/S0360-3016(03)00161-5)

Fig. 4 Relationship between plasma MMP-9 and leukocyte count for baseline and biweekly values during and after RT. International Journal of Radiation Oncology • Biology • Physics 2003 56, 1161-1169DOI: (10.1016/S0360-3016(03)00161-5)

Fig. 5 Temporal variation of MMP-3 plasma assays. Heavy dotted horizontal lines denote normal range (24 ± 8 ng/mL). International Journal of Radiation Oncology • Biology • Physics 2003 56, 1161-1169DOI: (10.1016/S0360-3016(03)00161-5)

Fig. 6 Temporal variation of lung clearance of inhaled DTPA aerosol, expressed as the biologic half-time and normalized to baseline values of 100%. Reduced half-time values of Subjects 2 and 7 during the first 100 days corroborated diagnosis of radiation pneumonitis. International Journal of Radiation Oncology • Biology • Physics 2003 56, 1161-1169DOI: (10.1016/S0360-3016(03)00161-5)